+

TN2009000182A1 - Compounds and methods for inhibiting the interaction of bcl proteins with binding partners - Google Patents

Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Info

Publication number
TN2009000182A1
TN2009000182A1 TNP2009000182A TN2009000182A TN2009000182A1 TN 2009000182 A1 TN2009000182 A1 TN 2009000182A1 TN P2009000182 A TNP2009000182 A TN P2009000182A TN 2009000182 A TN2009000182 A TN 2009000182A TN 2009000182 A1 TN2009000182 A1 TN 2009000182A1
Authority
TN
Tunisia
Prior art keywords
compounds
inhibiting
interaction
methods
binding partners
Prior art date
Application number
TNP2009000182A
Other languages
English (en)
Inventor
Alfredo C Castro
Edward B Holson
Brian T Hopkins
Nii O Koney
Daniel A Snyder
Thomas T Tibbitts
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of TN2009000182A1 publication Critical patent/TN2009000182A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2009000182A 2006-11-15 2009-05-08 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners TN2009000182A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
PCT/US2007/023941 WO2008060569A1 (fr) 2006-11-15 2007-11-14 Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison

Publications (1)

Publication Number Publication Date
TN2009000182A1 true TN2009000182A1 (en) 2010-10-18

Family

ID=39064388

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000182A TN2009000182A1 (en) 2006-11-15 2009-05-08 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Country Status (21)

Country Link
US (2) US7842815B2 (fr)
EP (1) EP2094673B1 (fr)
JP (2) JP2010510214A (fr)
KR (1) KR101530721B1 (fr)
CN (1) CN101583606B (fr)
AU (1) AU2007319848B2 (fr)
BR (1) BRPI0718606A2 (fr)
CA (1) CA2669596C (fr)
EC (1) ECSP099398A (fr)
ES (1) ES2537762T3 (fr)
GT (1) GT200900123A (fr)
HK (1) HK1130057A1 (fr)
IL (1) IL198597A (fr)
MA (1) MA31067B1 (fr)
MX (1) MX2009005184A (fr)
MY (1) MY156754A (fr)
NO (1) NO20092306L (fr)
NZ (1) NZ577243A (fr)
RU (1) RU2449996C2 (fr)
TN (1) TN2009000182A1 (fr)
WO (1) WO2008060569A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2952522B1 (fr) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilisés et leurs utilisations
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
WO2009099677A2 (fr) * 2008-02-08 2009-08-13 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques thérapeutiques
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
JP6342808B2 (ja) 2011-10-18 2018-06-13 エイルロン セラピューティクス,インコーポレイテッド ペプチドミメティック大環状化合物
US8945853B2 (en) 2012-02-06 2015-02-03 Discoverx Corporation Detection of intracellular binding events by measuring protein abundance
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
AU2013221433B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN103656642A (zh) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 预防和治疗结直肠癌的方法和试剂
WO2014078014A2 (fr) 2012-11-14 2014-05-22 Metabolix, Inc. Production de sels de 4-hydroxybutyrate à l'aide de matières premières biosourcées
WO2014138429A2 (fr) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leur utilisation dans la régulation de hif1alpha
CN112274641A (zh) 2014-01-28 2021-01-29 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2017044633A1 (fr) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques en tant que modulateurs de mcl-1
KR102545392B1 (ko) 2016-03-28 2023-06-20 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197051A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
WO2021233948A1 (fr) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de traitement d'une infection pulmonaire par un pathogène
WO2022008464A1 (fr) 2020-07-06 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinaison d'antibiotiques anti néoplasiques et d'inhibiteurs de bcl-2 pour le traitement de la leucémie myéloïde aiguë (lma) entraînée par npm-1
WO2025087879A2 (fr) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppression de la voie de signalisation pi3kgamma/akt pour le traitement de leucémie myéloïde aiguë

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
AU649421B2 (en) 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
EP0623615B1 (fr) * 1993-05-01 1999-06-30 MERCK PATENT GmbH Dérivés de 1-phényl-oxazolidin-2-one substitués, leur préparation et leur utilisation comme antagonistes du récepteur d'adhésion
JPH09505590A (ja) 1993-11-24 1997-06-03 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 新規なイソオキサゾリンおよびイソオキサゾールフィブリノーゲン受容体拮抗剤
NZ278667A (en) 1994-03-09 2000-12-22 Pfizer Use of isoxazoline derivatives to inhibit TNF production
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
CA2262117A1 (fr) 1996-08-16 1998-02-19 The Dupont Merck Pharmaceutical Company Amidinophenyl-pyrrolidines, -pyrrolines et -isoxazolidines et leurs derives
WO1998016830A2 (fr) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Systeme de criblage par gouttelettes
ES2387211T3 (es) 1997-05-07 2012-09-18 University Of Pittsburgh Inhibidores de proteínas isoprenil transferass
AU7105800A (en) 1999-09-01 2001-03-26 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
IL159110A0 (en) 2001-05-30 2004-06-01 Univ Michigan Small molecule antagonists of bcl2 family proteins
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
US7851637B2 (en) 2004-06-17 2010-12-14 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
WO2006009907A2 (fr) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Traitement d'infections bacteriennes au moyen de composes d'isoxazolidine
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法

Also Published As

Publication number Publication date
IL198597A0 (en) 2010-02-17
CA2669596A1 (fr) 2008-05-22
CN101583606A (zh) 2009-11-18
RU2009121808A (ru) 2010-12-20
KR101530721B1 (ko) 2015-06-22
IL198597A (en) 2014-03-31
US8461191B2 (en) 2013-06-11
US20110160259A1 (en) 2011-06-30
US20070161690A1 (en) 2007-07-12
BRPI0718606A2 (pt) 2013-12-17
US20080306127A9 (en) 2008-12-11
WO2008060569A1 (fr) 2008-05-22
MA31067B1 (fr) 2010-01-04
RU2449996C2 (ru) 2012-05-10
GT200900123A (es) 2011-09-02
NO20092306L (no) 2009-08-17
NZ577243A (en) 2011-12-22
MX2009005184A (es) 2009-10-12
JP2010510214A (ja) 2010-04-02
AU2007319848B2 (en) 2012-05-03
EP2094673A1 (fr) 2009-09-02
ECSP099398A (es) 2009-07-31
ES2537762T3 (es) 2015-06-11
EP2094673B1 (fr) 2015-04-08
AU2007319848A1 (en) 2008-05-22
US7842815B2 (en) 2010-11-30
MY156754A (en) 2016-03-31
JP2014055156A (ja) 2014-03-27
CN101583606B (zh) 2015-04-08
KR20090082284A (ko) 2009-07-29
HK1130057A1 (en) 2009-12-18
CA2669596C (fr) 2014-09-30

Similar Documents

Publication Publication Date Title
TN2009000182A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
IL179904A0 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
JO2917B1 (en) Compounds and methods to inhibit the interaction between BCL and binding partners
MY153232A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
TN2010000169A1 (en) Molecules and methods for modulating complement component
WO2007139960A3 (fr) Composés modulant l'activité de hsp90 et méthodes d'identification de ces composés
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
SG10201407457UA (en) Iap bir domain binding compounds
MX2010001565A (es) Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90.
MX2009008547A (es) Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer.
TW200640924A (en) VEGF-R2 inhibitors and methods
TW200716624A (en) Compounds for modulating TRPV3 function
TW200738234A (en) Triazole compounds that modulate HSP90 activity
TW200602029A (en) Inhibitors of IAP
WO2009009041A3 (fr) Compositions et procédés permettant de moduler une cascade de kinases
MY153243A (en) Compound for inhibiting mitotic progression
PH12012501813A1 (en) Iap bir domain binding compounds
WO2007059154A3 (fr) Traitement de cancers a resistance acquise a des inhibiteurs de kit
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
MY155908A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
TNSN06418A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
TW200621265A (en) Composition for treating tumor and/or preventing tumor transfer and recurrence
TW200800952A (en) Biaryl compositions and methods for modulating a kinase cascade
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载